Literature DB >> 6610709

Immune function in severe, active rheumatoid arthritis: a relationship between peripheral blood mononuclear cell proliferation to soluble antigens and mononuclear cell subset profiles.

B Haraoui, R L Wilder, D G Malone, J B Allen, I M Katona, S M Wahl.   

Abstract

We have previously reported that patients with active rheumatoid arthritis and depressed in vitro peripheral blood mononuclear cell proliferation to soluble recall antigens (anergic subgroup) improve clinically after repeated short-term leukapheresis, whereas patients with normal responses (nonanergic subgroup) do not. This observation prompted us to examine the mononuclear cell subset profiles in the peripheral blood of anergic and nonanergic seropositive rheumatoid arthritis patients with severe, active, clinically similar disease not taking long-acting anti-rheumatic drugs. In the present study, 42 patients were categorized as anergic (n = 14) or nonanergic (n = 28) on the basis of in vitro peripheral blood mononuclear cell proliferation to soluble recall antigens. The anergic patients had a decreased frequency of OKT4+ mononuclear cells (p less than 0.01), and an increased frequency of OKT8+ cells (p less than 0.02), with a lower OKT4+ :OKT8+ ratio (p less than 0.01) than the nonanergic patients. Anergic patients also had a higher frequency of HLA-DR+ mononuclear cells and HLA-DR+ T cells (p less than 0.001). About 50% of the OKT8+ cells were HLA-DR+, whereas only about 20% of the OKT4+ population expressed HLA-DR antigens. These data suggest that the decreased lymphocyte function described in the anergic patient subgroup is associated with characteristic peripheral blood mononuclear cell subset profiles. Moreover, when considered in the context of other data indicating that anergic patients have characteristic synovial immunopathologic abnormalities, these data provide insight into potential pathogenic mechanisms of this disorder.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6610709

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Autoantibodies to recombinant lipocortin-1 in rheumatoid arthritis and systemic lupus erythematosus.

Authors:  N J Goulding; M R Podgorski; N D Hall; R J Flower; J L Browning; R B Pepinsky; P J Maddison
Journal:  Ann Rheum Dis       Date:  1989-10       Impact factor: 19.103

2.  Basis for defective proliferation of peripheral blood T cells to anti-CD2 antibodies in primary Sjögren's syndrome.

Authors:  R Gerli; A Bertotto; E Agea; L Lanfrancone; C Cernetti; F Spinozzi; P Rambotti
Journal:  J Clin Invest       Date:  1990-12       Impact factor: 14.808

3.  Depressed T cell reactivity to recall antigens in Crohn's disease before and after surgical resection.

Authors:  G D'Haens; M Hiele; P Rutgeerts; K Geboes; J L Ceuppens
Journal:  Gut       Date:  1994-12       Impact factor: 23.059

4.  Activation pathways of synovial T lymphocytes. Expression and function of the UM4D4/CDw60 antigen.

Authors:  D A Fox; J A Millard; L Kan; W S Zeldes; W Davis; J Higgs; F Emmrich; R W Kinne
Journal:  J Clin Invest       Date:  1990-10       Impact factor: 14.808

5.  Absence of peripheral blood T cell responses to "shared epitope' containing peptides in recent onset rheumatoid arthritis.

Authors:  G J McColl; J Hammer; L C Harrison
Journal:  Ann Rheum Dis       Date:  1997-04       Impact factor: 19.103

6.  Immune function in severe, active rheumatoid arthritis. A relationship between peripheral blood mononuclear cell proliferation to soluble antigens and synovial tissue immunohistologic characteristics.

Authors:  D G Malone; S M Wahl; M Tsokos; H Cattell; J L Decker; R L Wilder
Journal:  J Clin Invest       Date:  1984-10       Impact factor: 14.808

7.  Expression and function of CD5 and CD28 in patients with rheumatoid arthritis.

Authors:  J Verwilghen; V Corrigall; R M Pope; R Rodrigues; G S Panayi
Journal:  Immunology       Date:  1993-09       Impact factor: 7.397

8.  Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis.

Authors:  A P Cope; M Londei; N R Chu; S B Cohen; M J Elliott; F M Brennan; R N Maini; M Feldmann
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

9.  Hepatitis B vaccination. Response of alcoholic with and without liver injury.

Authors:  C Mendenhall; G A Roselle; L A Lybecker; L E Marshall; C J Grossman; S A Myre; R E Weesner; D D Morgan
Journal:  Dig Dis Sci       Date:  1988-03       Impact factor: 3.199

10.  Depressed T-cell reactivity to recall antigens in rheumatoid arthritis.

Authors:  J Verwilghen; S Vertessen; E A Stevens; J Dequeker; J L Ceuppens
Journal:  J Clin Immunol       Date:  1990-03       Impact factor: 8.317

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.